Paclitaxel is an antineoplastic drug used against a variety of tumors, but its low aqueous solubility and active removal caused by P-glycoprotein in the intestinal cells hinder its oral administration. In our study, new type of stabilized Pluronic micelles were developed and evaluated as carriers for paclitaxel delivery via oral or intravenous route. The pre-stabilized micelles were loaded with paclitaxel by simple solvent/evaporation technique achieving high 4
Introduction
Polymeric micelles present a great potential as drug delivery systems for compounds that are hydrophobic and exhibit poor bioavailability. The unique core-shell structure of micelles enables incorporation of poorly soluble drugs into the inner hydrophobic core thus improving their stability and bioavailability. The hydrophilic shell plays an important role for the in vivo behavior of the micelles, in particular their steric stabilization and ability to interact with the cells. According to some references polymeric micelles could facilitate drug transport by fluid phase endocytosis as well as to provide receptor mediated transport by functionalization of the shell (Torchilin, 2004; Mathot et al., 2007) .
The micelles of poly(ethylene oxide)-b-poly-(propylene oxide)-b-poly(ethylene oxide) (PEO-PPO-PEO) amphiphilic triblock copolymers are evaluated as drug and gene delivery systems, as well as in diagnostic imaging as carriers for various contrasting agents . PEO-PPO-PEO micelles can be prepared from commercially available copolymers (Pluronics) and combine several attractive properties, including resistance of the PEO shell to protein adsorption, ability of the temperature responsive PPO core to solubilize water-insoluble compounds and availability of hydroxyl groups to which receptor-specific with capability to disturb the effect of intestinal P-gp and/or cytocrome P450. In this context, the combination between cyclodextrins and poly(anhydride) nanoparticles yielded oral bioavailability up to 85 % in rat. In this approach, the cyclodextrin permits to promote the encapsulation of the lipophilic drug into the nanoparticles and to inhibit the activity of the Pgp, whereas the function of poly(anhydride) nanoparticles is to develop bioadhesive interactions within the gastrointestinal mucosa and control the release of their content (Agüeros et al., 2010) .
The aim of this work was to prepare, characterize and evaluate the pharmacokinetics of paclitaxel incorporated in stabilized Pluronic micelles. The stabilization of micelles by crosslinking of their core was performed aiming to prevent disaggregation of micelles upon dilution in physiological fluids. On the other hand, drug encapsulation in micelles can diminish drug extravasation to normal tissues and provide a passive drug targeting to tumors via the enhanced permeability and retention effect (EPR) (Maeda et al., 2000) . This increased permeability is favorised by the prolonged circulation of micelles and lack of renal clearance (Han et al., 2006; Batrakova et al., 2008) . On the other hand, Pluronic copolymers (as other pharmaceutical excipients) may inhibit the activity of drug efflux transporters such as P-gp, MRPs and BCRP Thomas et al., 2003; Huang et al., 2008) . Thus, the combination of these properties with the fact that the shell of polymeric micelles could establish interactions with the cells may be an adequate strategy to (i) increase the oral bioavailability and/or (ii) promote the efficacy of the loaded drug. 
Materials and methods

Materials
Preparation of stabilized Pluronic micelles (PM)
PEO 43 PPO 15 PEO 43 (5 g) was dissolved in 250 ml double distilled water in a glass vessel under stirring. Acetone solution of PETA (0.05g/ ml) was added and the temperature of the solution was increased to 60 o C. Argon was bubbled through the solution for 45 min, followed by irradiation with a full spectrum UV light (TQ 150 Original Hanau high-pressure 150 W mercury lamp provided with a quartz tube and a cooling quartz jacket) for 45 min. The stabilized polymeric micelles were purified by dialysis against water using a cellulose membrane (Sigma, cutoff 12,000 gmol -1 ) for 14 days. Finally, the micelles dispersion was frozen and subsequently lyophilized.
Loading of pre-stabilized Pluronic micelles with rhodamine (R-PM)
The pre-stabilized micelles were fluorescently labelled with rhodamine B by solvent evaporation technique. For this purpose, 10 ml ethanol solution of rhodamine (concentration 0.1 mg/ml, 0.15 mg/ml or 0.3 mg/ml) was added to 10 ml of aqueous dispersion of the stabilized micelles (3 mg/ml) and the compounds were incubated for 24h. The ethanol was evaporated under reduced pressure (Buchi-144, Switzerland) and dialysis of the aqueous dispersion towards distilled water (Sigma, cutoff 12,000 g mol ) was performed in order to eliminate the free rhodamine. Finally, the purified aqueous dispersion containing rhodamine loaded micelles was lyophilized (Genesis 12EL, Virtis, USA) using sucrose as cryoprotector (5 % w/v).
Loading of pre-stabilized Pluronic micelles with paclitaxel (PTX-PM)
Ten ml of ethanol solution of paclitaxel (concentration 0.1 mg/ml, 0.15 mg/ml or 0.3 mg/ml) was added to 10 ml of aqueous dispersion of the pre-stabilized micelles (3 mg/ml) and the compounds were incubated for 24h. The ethanol was evaporated under reduced pressure Switzerland) and the resulted micelle dispersion was filtered (0.22 μm). The filter was rinsed with ethanol and these fractions were determined for non-encapsulated paclitaxel.
The aqueous dispersion containing paclitaxel loaded micelles was lyophilized (Genesis 12EL, Virtis, USA) using sucrose as cryoprotector (5 % w/v).
Characterisation of the micelles
Size and zeta-potential were determined by photon correlation spectroscopy and electrophoretic laser doppler anemometry using a Zetamaster analyzer (Malvern Instruments, 
Determination of drug loading
The amount of rhodamine incorporated into the R-PM was determined by spectrofluorimetry at wavelength λ ex =540nm and λ em =580nm (GENios, Austria). The marker loading was calculated as a difference between its initial concentration and the concentration found in the aqueous fractions collected after the dialysis procedure. For the calculations standard curve of rhodamine B in distilled water was prepared in the concentration range of 0.2-4.0 μg/ml (r>0.9978).
The amount of paclitaxel incorporated into the PTX-PM was calculated as a difference between its initial concentration and the concentration found in the ethanol rinsing fractions.
Paclitaxel was determined by HPLC method, in particular the chromatographic system was an Agillent 1100 series (Waldbornn, Germany), coupled with a UV diode array detection system (25). Data were analyzed using the Chemstation G2171 program (B.01.03). The separation of PTX was carried out at 30ºC on a reversed-phase 150 x 3 mm C18 Phenomenex Gemini column (particle size 5 m). The mobile phase, pumped at 0.5 ml/min, was 50:50 acetonitrile -phosphate buffer (0.02 M, pH=2.0) and effluent was monitored with UV detection at 228 nm. For the calculations standard curve of paclitaxel was prepared in the concentration range of 1.25-80.0 μg/ml (r>0.9991). The limit of quantification was calculated as 40 ng/ml with a relative standard deviation of 5.2 %.
The equations used for calculation of theoretical drug loading, actual drug loading and encapsulation efficiency are given bellow:
Distribution of R-PM within the gut
The study was performed in compliance with the regulations of the responsible committee of the University of Navarra in line with the European legislation on animal experiments (86/609/EU). Rhodamine B labelled micelles were administered in the form of aqueous suspensions (10 mg/ml) to fasted Wistar rats orally. The animals were sacrificed by cervical dislocation at 1, 3 and 8 h post administration. The abdominal cavity was opened and GIT was removed and divided into three regions: stomach, small intestine and caecum. Each segment was opened lengthwise along the mesentery and rinsed with phosphate saline buffer Theoretical drug loading (%) = Weights of drug and stabilized micelles
Weight of drug initially added X 100
Actual drug loading (%) = Weight of drug loaded micelles
Weight of drug incorporated into micelles X 100
Encapsulation efficiency (%) = Theoretical drug loading Actual drug loading X 100 (pH 7.4) in order to eliminate the lumen contents. Further, each segment was cut into portions of 2 cm length and digested in 1 ml of 3N NaOH for 24 h (Arbos et al., 2002) . Rhodamine was extracted with 2 ml methanol, vortexed for 1 min and centrifuged at 4000 rpm for 10 min. Aliquots (1 ml) of the supernatants were assayed for rhodamine by spectrofluorimetry (GENios, Austria) to estimate the fraction of the micelles within gastrointestinal mucosa.
Calculations were made using standard curves of rhodamine prepared by addition of rhodamine solutions in 3N NaOH (0.5-10 g/ml) to tissue segments following the same treatment steps.
Control rhodamine solution (119 μg/ml) was administered to rats and the presence of rhodamine within gastrointestinal mucosa was determined following the same procedures as above.
Pharmacokinetic study in mice
Animal experiments were performed in compliance with regulations of the responsible Ethical Committee of the University of Navarra (protocol number 076-06) in strict accordance with the European legislation in animal experiments. Female C57BL/6J mice (average weight 20 g) (Harlan, Spain) were housed under normal conditions with free access to food and water. The animals were placed in metabolic cages and fasted overnight to prevent corpophagia but allowing free access to water.
For the pharmacokinetic study, the mice were divided at random into 4 groups (n=5). The first two groups received orally a single dose (10 mg paclitaxel/kg) of either (i) commercial Taxol    or (ii) paclitaxel-loaded micelles (PTX-PM). Besides, Taxol  and PTX-PM were also intravenously administered to the other two groups of mice at the same dose (10 mg/kg).
All the formulations were administered dispersed or dissolved in 1 ml of water (oral) or saline (intravenous). Blood samples of 200 l were collected at different times in tubes containing EDTA (Microvette® EDTA tripotassium salt; Sarstedt, Numbrecht, Germany).
The volemia was recovered via intraperitoneal injection of an equal volume of normal saline solution preheated at body temperature. Blood samples were centrifuged for 10 min at 10,000 rpm and the supernatant plasma fractions were stored at -80ºC until HPLC analysis.
HPLC quantification of paclitaxel in plasma samples
The amount of paclitaxel was determined in plasma by HPLC as described above.
Calibration curves were used for the conversion of the PTX/DCX chromatographic area to the concentration. Calibrator and quality control samples were prepared by adding appropriate volumes of standard PTX ethanol solution to drug free plasma. Calibration curves were designed over the range of 40-3200 ng/ml (r 2 >0,999). An aliquot (100 l) of plasma sample was mixed with 25 l of internal standard solution (docetaxel, 4 g/ml in methanol, previously evaporated). After vortex mixing, liquid-liquid extraction was accomplished by adding 4 ml of tert-buthylmethylether following vortex gentle agitation (1 min). The mixture was centrifuged for 10 min at 5000 rpm, the organic layer was transferred to a clean vial and evaporated until dry (Savant, Barcelona, Spain). Finally, the residue was dissolved in 125 l of reconstitution solution (acetonitrile/0,01M phosphate buffer, 50/50 v/v, pH=2.0) and transferred to auto-sampler vials, capped and placed in the HPLC auto sampler. A 100 l aliquot of each sample was injected onto the HPLC column.
Under these experimental conditions the run time was 14 min. The limit of quantification was calculated as 80 ng/ml with a relative standard deviation of 5.2 %. Accuracy values during the same day (intra-day assay) at low, medium and high concentrations of PTX was always within the acceptable limits (-1.81 and 3.49 %) at all concentrations tested.
Pharmacokinetic data analysis
The pharmacokinetic analysis of concentration-time data, obtained after the administration of the different PTX formulations, were analyzed using a noncompartimental model using 
Statistical analysis
The results were expressed as mean values  SD. The Mann-Withney U-test was used to investigate statistical differences. In all cases, p < 0.05 was considered to be significant. All calculations were performed using SPSS 
Results
Characterization of the micelles
The main physico-chemical properties of the micelles are presented in Table 1 . The resulted stabilized micelles have an average diameter less than 200 nm, narrow distribution and negative zeta-potential values. As shown, drug-loaded micelles did not differ in size compared to the non-loaded micelles. The latter is due to the fact that the dense poly-PETA network locks the micellar structure and does not allow any re-arrangement and expansion.
Physical stability of the stabilized micelles was evaluated by observation of their size and polydispersity with time. The size was measured in aqueous media with increasing salt concentration aiming to investigate the influence of the ionic strength. The ratio between the size observed after 24 hours in different media (aqueous dispersion, 0.154 M and 0.308 M NaCl solution) to initial size measured in distilled water was calculated (Figure 1 ). Since the size ratios were in a narrow range, the micelles were considered stable.
In order to evaluate the influence of the initial drug/stabilized micelles ratio on drug loading degree, different concentrations of rhodamine/ paclitaxel with respect to the micelle concentration were varied. The results demonstrated that the increase of the initial concentration from 1 to 1.5mg increased loading degree for both molecules (Figure 2 ).
However, further increase of initial paclitaxel concentration decreased encapsulation efficiency suggesting that the optimal ratio between initial paclitaxel and stabilized micelles was 1:20.
Gastrointestinal transit of the stabilized micelles
The study was performed using the stabilized micelles loaded with rhodamine (R-PM) as described above (an initial ratio 1:20). The study included oral administration of micelles and evaluation of the localization of rhodamine in the gastrointestinal mucosa. In parallel, control solution of rhodamine with a concentration similar to the rhodamine concentration into the micelles was administered. The results showed that the total amount of rhodamine within the gastrointestinal mucosa decreased with time ( Figure 3 ). In fact, one hour post administration about 40 % of the given dose was found in the mucosa (mainly in the stomach) whereas, 2 hours later, only 21 % of the rhodamine dose remained within the mucosa. The rhodamine dose remained 8 h post-administration (18 %) was similar to that found 3 h postadministration, which clearly demonstrated the prolonged transit of micellar rhodamine. In any case, these percentages were significantly higher (p<0.05) than those observed for the control solution of rhodamine (Figure 4) .
Pharmacokinetic study of paclitaxel when loaded in stabilized Pluronic micelles
For the pharmacokinetic study, Taxol for Taxol®, the plasma curve was characterised by a rapid decline in the paclitaxel plasma levels during the first 2 h after administration followed by a slow fall of drug concentrations till the end of the experiment (8 hours). Under these circumstances, the micelles provided higher AUC (1.2-fold) compared to Taxol (Table 2) . Further, when commercial Taxol  was administered to mice by the oral route, no PTX plasma levels were found ( Figure 6 ). On the contrary, when PTX was included into micelles, these formulations displayed drug levels in plasma for at least 8 h. The plasma curve was characterised by a high C max 30 min postadministration, only 3-times lower than that obtained with the same formulation i.v. administered (Table 2) , followed by a slow and almost constant decline during the following 8 hours. The oral bioavailability of paclitaxel when loaded into the stabilized Pluronic micelles was calculated to be about 0.9.
Dynamic core-shell micelles of PEO 43 PPO 15 PEO 43 copolymer were stabilized by UVinduced crosslinking of tetrafunctional acrylate, PETA, within the micelles according to procedure described elsewhere (Petrov et al., 2008) . Pentaerythritol tetraacrylate was applied as cross-linking agent because of its ability to form an interpenetrating network in which the polyether chains are physically entrapped. Previous studies have shown that the micelles obtained with large amount of PETA (10-50 mass% with respect to PPO fraction) are extremely stable and do not disaggregate upon dilution in water and organic solvents and maintain their integrity even when irradiated with ultrasound (Petrov et al., 2006) . In the case of aggregates stabilized with smaller amount of PETA (3 mass %), copolymer molecules can dissociate from the polymer network resulting in aggregates dissociation (Li et al., 2007) .
Thus, one may play with the long-term stability of the micelles by tuning the density of poly-PETA network. Taking into account the above considerations, the cross-linking agent was used in a concentration of 30 % with respect to PPO fraction. This network does not decrease noticeably the loading capacity of PPO core and, on the other hand, does not influence the flexibility of extended hydrophilic PEO-chains of resulted stabilized micelles. The latter is very important taking into account that the mobility of hydrophilic chains on the periphery of drug carriers determines both the stability and the in vivo distribution of the particles. In this view, our observations showed that the size and polydispersity of the stabilized Pluronic micelles did not change even in the presence of electrolyte. This fact suggested that the PEO chains are extended and prevent any agglomeration of the micelles in the presence of electrolytes.
Two methods have been reported for loading of polymeric micelles with drug molecules, in particular physical and chemical loading (Jones and Leroux, 1999) . The second method includes formation of chemical bonds between drug molecule and polymeric carrier, usually during the process of micelles formation. In the present study the first method was applied.
The pre-stabilized micelles were loaded with fluorescent marker rhodamine B or with paclitaxel by solvent evaporation technique. Comparing both molecules, higher loading and encapsulation efficiency was achieved with paclitaxel. The latter fact was explained with the more hydrophobic nature of paclitaxel (logP of 3.5) than rhodamine (logP of 1.95).
Gastrointestinal transit of the stabilized micelles was evaluated by oral administration to rats. The most important finding was that the transit of the rhodamine-loaded micelles was prolonged compared to the control solution of free rhodamine. Thus, 8 hours after administration only 6 % of rhodamine applied in the form of solution was spread on the whole GIT versus 18 % for stabilized micelles (Figure 4 ). Another interesting point was that the micelles were concentrated in the small intestine of animals after oral administration (I3 and I4 portions in Figure 3 ). All of these results appear to be in line with previous studies about the interaction of micelles with the intestinal mucosa (Gaucher et al., 2010) . In fact, the size and hydrophilicity of the shell may limit their interaction with the gut contents and would favour the diffusion of these carriers through the mucus layer. Similar phenomenon has been previously reported for pegylated poly(anhydride) nanoparticles (Yoncheva et al., 2007) . The authors postulated that the "brush" layer of PEG-chains reduced an interaction between nanoparticles and mucin, which corresponded to better adhesion and facilitated their proximal contact with enterocytes. In the present study, the extended flexible PEO-chains in the micelle shell probably function in a similar way.
Intravenous administration of Taxol
 and PTX-PM into mice showed a significant improvement of pharmacokinetic parameters after administration of micellar paclitaxel (Table   2 ). More important, the higher MRT (about 5-times) and lower Cl values (about 2-fold)
indicated that PTX-PM formulation increased the time of systemic circulation. This fact could be explained with the protective "stealth" properties of micelle PEO-shell that hinders their recognition and uptake by the cells of RES. These results are in agreement with previous data published by Kabanov and collaborators (Kabanov et al., 2002) . This manuscript studied the pharmacokinetics and biodistribution of Pluronics after single i.v. administration and reported that these block copolymers remained in circulation a substantial period of time. The results obtained after oral administration of our stabilized micelles were even more interesting. The AUC calculated after oral administration of micelles was similar to that calculated for the i.v.
administration of Taxol  (Table 2) . On the other hand, the mean residence time of paclitaxel after oral administration of PTX-PM was almost two-times longer than that achieved after i.v.
administration of micelles and 9-times longer than Taxol to the absorptive surface of the enterocytes. On the other hand, it has been described that Pluronics and other non-ionic surfactants inhibit the activity of intestinal Pgp (Batrakova et al., 1998a; 1998b) . This fact has been explained by a combination of decreased ATPase activity and ATP depletion due to increased membrane fluidity (Batrakova et al., 2004; Bansal et al., 2009) . Nonetheless, studies performed on various cell models have shown that polymeric micelles could be internalized, with fluid-phase pinocytosis appearing as a major route (Allen et al., 1999; Luo et al., 2002 (Mathot et al., 2007) . Taking into account these reports, the results in the present study may be explained by an increased absorption of paclitaxel when loaded into the newly developed stabilized micelles, an absorption or translocation of micelles through the gastrointestinal mucosa or a combination of both phenomena.
In summary, the present study demonstrated the development of new, in particular stabilized micelles, as paclitaxel delivery system. The extended PEO-chains in the micelle shell probably enabled interactions between epithelial cells of gastrointestinal mucosa and micelles, which in turn prolonged gastric residence time of paclitaxel. In vivo study showed an improvement of pharmacokinetic parameters after intravenous and oral administration of PTX-loaded stabilized Pluronic micelles. Both, the prolonged gastric residence and the high physical stability of micelles achieved by cross-linking of micelle core, have been considered prerequisite for the efficient oral paclitaxel absorption. AUC area under the concentration-time curve from time 0 to 8; C max : peak concentration; T max : time to peak concentration; MRT: mean residence time; t 1/2z : half-life of the terminal phase. F: oral bioavailability. 
